Opko Health, Inc. (NYSE:OPK) entered into a definitive agreement to acquire Cytochroma Inc. from GrowthWorks Ltd. and others for approximately $300 million on January 8, 2013. As consideration, Opko Health will issue 20.52 million shares and an additional payment of $190 million in cash or additional shares of Opko Health common stock, at the buyer's election, upon the achievement of certain milestones relating to development and annual revenue. The transaction also includes acquisition of worldwide rights of Cytochroma's two products ReplideaTM and AlpharenTM by Opko Health, Inc. Post acquisition, Cytochroma's officers will join the Opko Health, Inc.'s management team and all other Cytochroma Inc. employees will be retained by Opko Health, Inc. The transaction subject to approval of Cytochroma's shareholders approval and is expected to close during the first quarter of 2013.

Mary V. Carroll, Esther L. Moreno, Christina C. Russo and Teddy D. Klinghoffer of Akerman Senterfitt LLP acted as a legal advisor for Opko. Global M&A GmbH acted as financial advisor for Cytochroma. Richard Kimel, Tom Fenton, James Leech, Anne Markle, Barbara Worndl, Aaron Collins and Grant Cansfield of Aird & Berlis LLP acted as legal advisors and Glen Sato of Cooley LLP acted as legal advisor for Cytochroma.